Infinia ML: IDP Software Vendor

Durham-based Infinia ML was founded in 2017 and raised $13M across 4 rounds - led by Carrick Capital Partners - before being acquired by healthcare revenue cycle management provider Aspirion. The company operated as an independent IDP vendor until January 1, 2026, when the acquisition formally closed and Infinia ML became an Aspirion operating subsidiary. Unlike text-focused competitors like Rossum and Mindee, Infinia ML's platform understands documents "in the context of visual structure and layout" using spatial named entity recognition, positioning it against layout-aware solutions like ABBYY and Hyperscience.

Buyers evaluating Infinia ML as a standalone IDP vendor should treat it as effectively off the market. Its roadmap and integrations are now driven by Aspirion's healthcare revenue cycle priorities.

Overview

Infinia ML competed in a crowded IDP market against Hyperscience, Rossum, Automation Hero, and Tungsten Automation - all better-capitalized or more narrowly specialized. At $13M raised and 36 employees at acquisition, Infinia ML remained small relative to that peer set, which constrained its ability to compete on breadth. Aspirion's acquisition resolved that tension by abandoning general-purpose positioning entirely: healthcare revenue cycle management is a document-intensive vertical with clear ROI on automation, and Aspirion gained a purpose-built ML extraction layer without building it internally.

The deal reflects a broader pattern in IDP: horizontal platforms at sub-scale are being absorbed into vertical software stacks where document automation is a feature, not a product. Aspirion now serves half of the ten largest health systems in the United States, giving Infinia ML's technology enterprise-scale distribution it could not have achieved independently.

Prior to acquisition, Everest Group ranked Infinia ML as an "Aspirant" in both Intelligent Document Processing and Unstructured Document Processing PEAK Matrix assessments in May 2023 - recognized but not yet scaled. The company maintained AWS Marketplace presence for cloud-first deployment alongside established platform vendors.

How Infinia ML Processes Documents

Infinia ML's core differentiator is spatial named entity recognition - processing documents within their visual structure and layout context rather than treating them as flat text streams. This matters in healthcare, where the spatial position of a denial code relative to a claim line, or a payment amount relative to a procedure code, changes the meaning of the extracted data. Pure OCR providers miss these relationships; Infinia ML's approach captures them.

The platform combines machine learning with document understanding to extract actionable data from complex, variable documents without relying on rigid templates. A human-in-the-loop validation layer handles edge cases and feeds corrections back into the model, improving accuracy over time on the specific document types each customer processes.

The research foundation behind the platform is substantial: Chief Scientist Larry Carin has contributed 44 papers to NeurIPS/NIPS since 2004, and the company earned "Best Machine Learning Company" recognition for two consecutive years alongside "Most Innovative Machine Learning Solutions Provider for Business" awards. That academic depth is now directed entirely at healthcare document types under Aspirion's ownership.

Use Cases

Healthcare Revenue Cycle Management

Following the Aspirion acquisition, Infinia ML's technology powers automated claims denial management, payment posting, and account resolution for hospitals and health systems. The platform processes explanation of benefits (EOB) documents, remittance advice, denial letters, and payer correspondence - extracting denial reasons, payment variances, and required documentation to accelerate resolution.

Ya Xue, PhD, Vice President of Data Science and co-founder of Infinia ML, noted that "Infinia ML's ability to accelerate its rate of impact through the tailored use of data and focused use cases that come from this partnership will be transformative." With Aspirion serving half of the ten largest U.S. health systems, the combined entity processes healthcare documents at a scale Infinia ML could not reach independently.

For a broader view of AI-powered claims workflows, see the healthcare claims automation guide.

Financial Services and Legal

Prior to the healthcare pivot, Infinia ML's spatial ML approach was applied to financial services, legal, and compliance document types - areas where layout relationships carry meaning in contracts, regulatory filings, and structured financial forms. These use cases are no longer the company's focus under Aspirion ownership, but the underlying technology remains applicable to any document type where visual structure affects data interpretation.

Technical Specifications

Resources

• AWS Marketplace Listing
• Aspirion Acquisition Announcement
• IDP Industry Coverage of Acquisition
• Carrick Capital: Infinia ML Research Profile
• PitchBook Company Profile
• Healthcare Claims Automation Guide
• Human-in-the-Loop Document Processing Guide
• Medical Document Processing Guide

Company Information

Infinia ML was founded in 2017 in Durham, North Carolina, and operated as an independent IDP vendor until its acquisition by Aspirion Health Resources. Aspirion - headquartered in Columbus, Georgia - is a healthcare revenue cycle management firm that had already partnered with Infinia ML before acquiring it. The acquisition was Aspirion's eighth in five years and its first technology-focused transaction.

Nick Giannasi, former Chief AI Officer of Change Healthcare and former Chief Product Officer of Ciox/Datavant, joined as Executive Chairman of Aspirion's AI group following the September 2023 announcement, bringing enterprise healthcare AI experience to the combined organization. The acquisition formally closed January 1, 2026, at which point Infinia ML became an Aspirion operating subsidiary. Acquisition price was not disclosed; PitchBook notes the final pre-acquisition deal type was PE Growth.